secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lunai Bioworks Inc. (LNAI)
CIK:        0001527728
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001731122-25-000312
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renovaro enters definitive merger with AI-driven Biosymetrics for 15M shares
----------------------------------------------------------------------------

- Renovaro issues 15M unregistered common shares to Biosymetrics stockholders for all outstanding shares; lock-up of CEO shares for 1 year.
- 3M of the issued shares held in escrow for 1 year to satisfy potential indemnification claims.
- Merger expected to close by March 15, 2025, subject to Biosymetrics stockholder approval and Nasdaq listing.
- Biosymetrics' Elion AI platform has partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures.
- Combined entity to focus on AI-driven biomarker discovery and precision medicine in cancer and other diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527728/000173112225000312/0001731122-25-000312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527728/000173112225000312/e6390_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-25-000312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer